Enhancement of radiosensitivity by a unique novel NF-B inhibitor, DHMEQ, in prostate cancer

N. Kozakai, E. Kikuchi, M. Hasegawa, E. Suzuki, H. Ide, A. Miyajima, Y. Horiguchi, J. Nakashima, K. Umezawa, N. Shigematsu, M. Oya

研究成果: Article査読

34 被引用数 (Scopus)


Background: Inducible activation of nuclear factor (NF)-B is one of the principal mechanisms through which resistant prostate cancer cells are protected from radiotherapy. We hypothesised that inactivation of inducible NF-B with a novel NF-B inhibitor, DHMEQ, would increase the therapeutic effects of radiotherapy.Methods:PC-3 and LNCaP cells were exposed to irradiation and/or DHMEQ. Cell viability, cell cycle analysis, western blotting assay, and NF-B activity were measured. The antitumour effect of irradiation combined with DHMEQ in vivo was also assessed.Results:The combination of DHMEQ with irradiation resulted in cell growth inhibition and G2/M arrest relative to treatment with irradiation alone. Inducible NF-B activity by irradiation was inhibited by DHMEQ treatment. The expression of p53 and p21 in LNCaP, and of 14-3-3 in PC-3 cells, was increased in the combination treatment. In the in vivo study, 64 days after the start of treatment, tumour size was 85.1%, 77.1%, and 64.7% smaller in the combination treatment group than that of the untreated control, DHMEQ-treated alone, and irradiation alone groups, respectively.Conclusion:Blockade of NF-B activity induced by radiation with DHMEQ could overcome radio-resistant responses and may become a new therapeutic modality for treating prostate cancer.

ジャーナルBritish Journal of Cancer
出版ステータスPublished - 2012 8月 7

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究


「Enhancement of radiosensitivity by a unique novel NF-B inhibitor, DHMEQ, in prostate cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。